Why we still need drugs for COVID‐19 and can't just rely on vaccines

por Robinson, Bruce W. S., Tai, Anna, Springer, Kyle
Publicado 2021

Discovery of new biomarkers for malignant mesothelioma

por Creaney, Jenette, Dick, Ian M., Robinson, Bruce W. S.
Publicado 2015

How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies

por Robinson, Bruce W.S., Redwood, Alec J., Creaney, Jenette
Publicado 2022

Tumor Antigen Cross-Presentation and the Dendritic Cell: Where it All Begins?

por McDonnell, Alison M., Robinson, Bruce W. S., Currie, Andrew J.
Publicado 2010

What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination

por Redwood, Alec J., Dick, Ian M., Creaney, Jenette, Robinson, Bruce W. S.
Publicado 2022

The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19

por Richardson, Peter J., Robinson, Bruce W. S., Smith, Daniel P., Stebbing, Justin
Publicado 2022

Auto-Antibodies to β-F1-ATPase and Vimentin in Malignant Mesothelioma

por Creaney, Jenette, Dick, Ian M., Yeoman, Deborah, Wong, Sarah, Robinson, Bruce W. S.
Publicado 2011

Malignant pleural effusion: from bench to bedside

por Psallidas, Ioannis, Kalomenidis, Ioannis, Porcel, Jose M., Robinson, Bruce W., Stathopoulos, Georgios T.
Publicado 2016

Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens

por Anyaegbu, Chidozie C., Lake, Richard A., Heel, Kathy, Robinson, Bruce W., Fisher, Scott A.
Publicado 2014

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

por Rozali, Esdy N., Hato, Stanleyson V., Robinson, Bruce W., Lake, Richard A., Lesterhuis, W. Joost
Publicado 2012

Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parame...

por McDonnell, Alison M., Cook, Alistair, Robinson, Bruce W. S., Lake, Richard A., Nowak, Anna K.
Publicado 2017

Association of Biomarker Levels with Severity of Asbestos-Related Diseases

por Park, Eun-Kee, Yates, Deborah H, Creaney, Jenette, Thomas, Paul S, Robinson, Bruce W, Johnson, Anthony R
Publicado 2012

Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo

por Greening, David W., Ji, Hong, Chen, Maoshan, Robinson, Bruce W. S., Dick, Ian M., Creaney, Jenette, Simpson, Richard J.
Publicado 2016

A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice

por Aston, Wayne J., Hope, Danika E., Nowak, Anna K., Robinson, Bruce W., Lake, Richard A., Lesterhuis, W. Joost
Publicado 2017

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma

por Creaney, Jenette, Segal, Amanda, Olsen, Nola, Dick, Ian M., Musk, A. W(Bill), Skates, Steven J., Robinson, Bruce W.
Publicado 2014

ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

por Morré, D. James, Hostetler, Brandon, Taggart, David J., Morré, Dorothy M., Musk, A. W., Robinson, Bruce W. S., Creaney, Jenette
Publicado 2016

Erratum to: ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms

por Morré, D. James, Hostetler, Brandon, Taggart, David J., Morré, Dorothy M., Musk, A. W., Robinson, Bruce W. S., Creaney, Jenette
Publicado 2016

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome

por Ma, Shaokang, Chee, Jonathan, Fear, Vanessa S., Forbes, Catherine A., Boon, Louis, Dick, Ian M., Robinson, Bruce W. S., Creaney, Jenette
Publicado 2019

Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation

por McDonnell, Alison M., Currie, Andrew J., Brown, Matthew, Kania, Kasia, Wylie, Ben, Cleaver, Amanda, Lake, Richard, Robinson, Bruce W.S.
Publicado 2012

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

por Creaney, Jenette, Sneddon, Sophie, Dick, Ian M., Dare, Hanne, Boudville, Neil, Musk, Arthur William, Skates, Steven J., Robinson, Bruce W. S.
Publicado 2013